financetom
Business
financetom
/
Business
/
Chewy Likely 'Out of the Doghouse' After Q1 Beat, Morgan Stanley Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Chewy Likely 'Out of the Doghouse' After Q1 Beat, Morgan Stanley Says
May 30, 2024 11:06 AM

01:37 PM EDT, 05/30/2024 (MT Newswires) -- Chewy (CHWY) is likely "out of the doghouse" after delivering better than expected Q1 revenue with a large EBITDA beat and launching its first buyback program, Morgan Stanley said in a note.

"CHWY called out encouraging green shoots with positive pet ownership trends and inflecting customer metrics," Morgan Stanley said. "With a 1Q sales beat and positive green shoots, we now view 2Q and FY24 revenue guidance as conservative."

The report also said there is a real probability for a consistent beat and raise on both the top- and bottom-line through FY24 if the pet macro continues to recover.

Morgan Stanley said its bull thesis remains on track, keeping the stock overweight while raising its price target to $28 from $27.

Price: 22.08, Change: +0.57, Percent Change: +2.67

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
US OKs sale of missiles to Poland and the Netherlands for $2 bln
US OKs sale of missiles to Poland and the Netherlands for $2 bln
Apr 24, 2024
WASHINGTON, April 24 (Reuters) - The U.S. State Department has approved the potential sale of advanced anti-radiation guided missiles with an extended range to Poland for about $1.3 billion and to the Netherlands for about $700 million, the Pentagon said on Wednesday. The principal contractor for both will be Northrop Grumman ( NOC ) , according to the Pentagon. ...
Amneal Pharmaceuticals Cleared by FDA to Sell Generic Version of Nasal Spray to Treat Opioid Overdose -- Shares Rise
Amneal Pharmaceuticals Cleared by FDA to Sell Generic Version of Nasal Spray to Treat Opioid Overdose -- Shares Rise
Apr 24, 2024
03:25 PM EDT, 04/24/2024 (MT Newswires) -- Amneal Pharmaceuticals ( AMRX ) rallied Wednesday after the US Food and Drug Administration approved its generic version of the nasal spray used to treat opioid overdose. Amneal's Naloxone HCI nasal spray is the generic version of OTC Narcan HCI nasal spray. Emergent BioSolutions ( EBS ) owns the trademark. AMRX shares were...
-- JD Bancshares Maintains Dividend at $0.29 Per Share; Payable May 10 to Shareholders of Record May 3
-- JD Bancshares Maintains Dividend at $0.29 Per Share; Payable May 10 to Shareholders of Record May 3
Apr 24, 2024
03:11 PM EDT, 04/24/2024 (MT Newswires) -- Price: 22.03, Change: +2.42, Percent Change: +12.34 ...
Capricor Therapeutics Gets Another Type-B Meeting With FDA for Duchenne Muscular Dystrophy Investigational Drug
Capricor Therapeutics Gets Another Type-B Meeting With FDA for Duchenne Muscular Dystrophy Investigational Drug
Apr 24, 2024
03:21 PM EDT, 04/24/2024 (MT Newswires) -- Capricor Therapeutics ( CAPR ) said Wednesday the US Food and Drug Administration granted another Type-B meeting in Q2 to move ahead with the biologics license application for CAP-1002 for treating Duchenne muscular dystrophy. The company said it will share safety and efficacy data from the open-label extension study with the FDA in...
Copyright 2023-2026 - www.financetom.com All Rights Reserved